Sarepta turns to Duke’s CRISPR work for next-gen DMD therapies

FierceBiotech – Sarepta has been signing a series of new R&D pacts since its controversial Duchenne muscular dystrophy (DMD) drug approval last fall, and today it’s penned a deal for one of the hottest research areas around: CRISPR.

In a deal with Duke University (financial terms were not disclosed), Sarepta gains an option for an exclusive license for this form of the gene-editing tech, which comes out of the lab of Charles Gersbach, Ph.D.

Read more at FierceBiotech.

News Image
muscle fibers from DMD research
Action
Industry
Image Citation

NIHCC BY-NC 2.0